ProSomnus non-inferior to CPAP therapy for the treatment of moderate to severe OSA
The First Line Obstructive Sleep Apnea Treatment study (FLOSAT) clinical trial assessing ProSomnus, a CPAP alternative for the treatment...
ProSomnus non-inferior to CPAP therapy for the treatment of moderate to severe OSA
Increased cardiovascular risks for people with obstructive sleep apnoea
Obstructive sleep apnoea could directly cause early cognitive decline
Guy’s and St Thomas’ first in the UK to provide new sleep apnoea treatment
Journal Watch 14/12/2022